NeurAxis (NRXS) Competitors $2.42 +0.01 (+0.21%) Closing price 09/12/2025 03:58 PM EasternExtended Trading$2.41 -0.01 (-0.62%) As of 09/12/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock NRXS vs. HYPR, BDMD, APYX, VANI, ICCM, NTRB, LUNG, QTI, TELA, and CTSOShould you be buying NeurAxis stock or one of its competitors? The main competitors of NeurAxis include Hyperfine (HYPR), Baird Medical Investment (BDMD), Apyx Medical (APYX), Vivani Medical (VANI), IceCure Medical (ICCM), Nutriband (NTRB), Pulmonx (LUNG), QT Imaging (QTI), TELA Bio (TELA), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry. NeurAxis vs. Its Competitors Hyperfine Baird Medical Investment Apyx Medical Vivani Medical IceCure Medical Nutriband Pulmonx QT Imaging TELA Bio Cytosorbents NeurAxis (NASDAQ:NRXS) and Hyperfine (NASDAQ:HYPR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, dividends and profitability. Which has stronger earnings & valuation, NRXS or HYPR? NeurAxis has higher earnings, but lower revenue than Hyperfine. Hyperfine is trading at a lower price-to-earnings ratio than NeurAxis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNeurAxis$3.22M7.44-$14.63M-$0.99-2.45Hyperfine$12.89M8.66-$40.72M-$0.52-2.73 Does the media favor NRXS or HYPR? In the previous week, Hyperfine had 1 more articles in the media than NeurAxis. MarketBeat recorded 2 mentions for Hyperfine and 1 mentions for NeurAxis. Hyperfine's average media sentiment score of 0.95 beat NeurAxis' score of -1.00 indicating that Hyperfine is being referred to more favorably in the news media. Company Overall Sentiment NeurAxis Negative Hyperfine Positive Do analysts rate NRXS or HYPR? NeurAxis presently has a consensus target price of $7.00, suggesting a potential upside of 188.66%. Hyperfine has a consensus target price of $1.28, suggesting a potential downside of 9.62%. Given NeurAxis' stronger consensus rating and higher possible upside, equities research analysts clearly believe NeurAxis is more favorable than Hyperfine.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeurAxis 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Hyperfine 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Do insiders and institutionals have more ownership in NRXS or HYPR? 11.8% of NeurAxis shares are held by institutional investors. Comparatively, 15.0% of Hyperfine shares are held by institutional investors. 26.4% of NeurAxis shares are held by company insiders. Comparatively, 31.0% of Hyperfine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Is NRXS or HYPR more profitable? Hyperfine has a net margin of -364.54% compared to NeurAxis' net margin of -492.76%. NeurAxis' return on equity of 0.00% beat Hyperfine's return on equity.Company Net Margins Return on Equity Return on Assets NeurAxis-492.76% N/A -641.25% Hyperfine -364.54%-84.82%-69.39% Which has more volatility and risk, NRXS or HYPR? NeurAxis has a beta of 3.1, meaning that its stock price is 210% more volatile than the S&P 500. Comparatively, Hyperfine has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. SummaryHyperfine beats NeurAxis on 10 of the 16 factors compared between the two stocks. Get NeurAxis News Delivered to You Automatically Sign up to receive the latest news and ratings for NRXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NRXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NRXS vs. The Competition Export to ExcelMetricNeurAxisElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$23.89M$43.73M$5.87B$10.13BDividend YieldN/AN/A5.68%4.60%P/E Ratio-1.323.9974.5225.93Price / Sales7.44221.57517.44183.79Price / CashN/A41.3637.5660.44Price / Book-8.982.4512.166.29Net Income-$14.63M-$2.66M$3.28B$270.77M7 Day Performance-0.21%-0.38%0.87%3.88%1 Month Performance-1.42%12.66%4.96%4.88%1 Year Performance-18.35%225.19%60.75%26.01% NeurAxis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NRXSNeurAxis2.0035 of 5 stars$2.43+0.2%$7.00+188.7%-21.8%$23.89M$3.22M-1.3219Negative NewsShort Interest ↑Gap UpHYPRHyperfine1.3422 of 5 stars$1.27+6.7%$1.28+1.0%+42.0%$93.51M$12.89M-2.44190BDMDBaird Medical InvestmentN/A$2.44-1.2%N/AN/A$88.25MN/A0.00N/APositive NewsAPYXApyx Medical2.4742 of 5 stars$2.06flatN/A+69.4%$77.91M$48.10M-4.58270Short Interest ↓VANIVivani Medical2.6892 of 5 stars$1.28flat$4.00+212.5%-2.4%$75.83MN/A-2.8420ICCMIceCure Medical2.4948 of 5 stars$1.03-1.9%$2.39+131.6%+56.4%$72.13M$3.29M-6.4460Short Interest ↑NTRBNutriband2.9665 of 5 stars$6.08-2.9%$13.00+113.8%+63.6%$69.82M$2.14M-6.7610Earnings ReportShort Interest ↓LUNGPulmonx3.7081 of 5 stars$1.69-0.6%$7.66+353.5%-79.2%$69.27M$83.79M-1.18250Positive NewsQTIQT ImagingN/A$2.52+1.6%N/A+379.4%$68.38M$4.00M0.00N/ATELATELA Bio2.78 of 5 stars$1.60-1.2%$4.50+181.3%-39.2%$64.18M$69.30M-1.43120Positive NewsCTSOCytosorbents2.3229 of 5 stars$1.00+1.6%$5.50+451.1%-11.5%$61.66M$35.60M-5.87220Positive News Related Companies and Tools Related Companies Hyperfine Alternatives Baird Medical Investment Alternatives Apyx Medical Alternatives Vivani Medical Alternatives IceCure Medical Alternatives Nutriband Alternatives Pulmonx Alternatives QT Imaging Alternatives TELA Bio Alternatives Cytosorbents Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NRXS) was last updated on 9/13/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredOctober 16 Changes the Microchip Game — and InvestingWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeurAxis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeurAxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
